OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Keep off the grass? Cannabis, cognition and addiction
H. Valerie Curran, Tom P. Freeman, Claire Mokrysz, et al.
Nature reviews. Neuroscience (2016) Vol. 17, Iss. 5, pp. 293-306
Open Access | Times Cited: 360
H. Valerie Curran, Tom P. Freeman, Claire Mokrysz, et al.
Nature reviews. Neuroscience (2016) Vol. 17, Iss. 5, pp. 293-306
Open Access | Times Cited: 360
Showing 1-25 of 360 citing articles:
New trends in cannabis potency in USA and Europe during the last decade (2008–2017)
Suman Chandra, Mohamed M. Radwan, Chandrani G. Majumdar, et al.
European Archives of Psychiatry and Clinical Neuroscience (2019) Vol. 269, Iss. 1, pp. 5-15
Closed Access | Times Cited: 404
Suman Chandra, Mohamed M. Radwan, Chandrani G. Majumdar, et al.
European Archives of Psychiatry and Clinical Neuroscience (2019) Vol. 269, Iss. 1, pp. 5-15
Closed Access | Times Cited: 404
Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting.
Mary Barna Bridgeman, Daniel T. Abazia
PubMed (2017) Vol. 42, Iss. 3, pp. 180-188
Closed Access | Times Cited: 390
Mary Barna Bridgeman, Daniel T. Abazia
PubMed (2017) Vol. 42, Iss. 3, pp. 180-188
Closed Access | Times Cited: 390
Cannabis use and cannabis use disorder
Jason P. Connor, Daniel Stjepanović, Bernard Le Foll, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 300
Jason P. Connor, Daniel Stjepanović, Bernard Le Foll, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 300
Dopamine and Addiction
Roy A. Wise, Mykel A. Robble
Annual Review of Psychology (2020) Vol. 71, Iss. 1, pp. 79-106
Open Access | Times Cited: 299
Roy A. Wise, Mykel A. Robble
Annual Review of Psychology (2020) Vol. 71, Iss. 1, pp. 79-106
Open Access | Times Cited: 299
Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta‐analysis
Tom P. Freeman, Sam Craft, Jack Wilson, et al.
Addiction (2020) Vol. 116, Iss. 5, pp. 1000-1010
Open Access | Times Cited: 253
Tom P. Freeman, Sam Craft, Jack Wilson, et al.
Addiction (2020) Vol. 116, Iss. 5, pp. 1000-1010
Open Access | Times Cited: 253
The neuropsychopharmacology of cannabis: A review of human imaging studies
Michael Bloomfield, Chandni Hindocha, Sebastian F Green, et al.
Pharmacology & Therapeutics (2018) Vol. 195, pp. 132-161
Open Access | Times Cited: 210
Michael Bloomfield, Chandni Hindocha, Sebastian F Green, et al.
Pharmacology & Therapeutics (2018) Vol. 195, pp. 132-161
Open Access | Times Cited: 210
Cannabis Addiction and the Brain: a Review
Amna Zehra, Jamie Burns, Christopher Kure Liu, et al.
Journal of Neuroimmune Pharmacology (2018) Vol. 13, Iss. 4, pp. 438-452
Open Access | Times Cited: 207
Amna Zehra, Jamie Burns, Christopher Kure Liu, et al.
Journal of Neuroimmune Pharmacology (2018) Vol. 13, Iss. 4, pp. 438-452
Open Access | Times Cited: 207
Cannabis and mental illness: a review
Darby J. E. Lowe, Julia Sasiadek, Alexandria S. Coles, et al.
European Archives of Psychiatry and Clinical Neuroscience (2018) Vol. 269, Iss. 1, pp. 107-120
Open Access | Times Cited: 202
Darby J. E. Lowe, Julia Sasiadek, Alexandria S. Coles, et al.
European Archives of Psychiatry and Clinical Neuroscience (2018) Vol. 269, Iss. 1, pp. 107-120
Open Access | Times Cited: 202
Medicinal use of cannabis based products and cannabinoids
Tom P. Freeman, Chandni Hindocha, Sebastian F Green, et al.
BMJ (2019), pp. l1141-l1141
Open Access | Times Cited: 202
Tom P. Freeman, Chandni Hindocha, Sebastian F Green, et al.
BMJ (2019), pp. l1141-l1141
Open Access | Times Cited: 202
How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review
Abigail M. Freeman, Kat Petrilli, Rachel Lees, et al.
Neuroscience & Biobehavioral Reviews (2019) Vol. 107, pp. 696-712
Open Access | Times Cited: 181
Abigail M. Freeman, Kat Petrilli, Rachel Lees, et al.
Neuroscience & Biobehavioral Reviews (2019) Vol. 107, pp. 696-712
Open Access | Times Cited: 181
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Tom P. Freeman, Chandni Hindocha, Gianluca Baio, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 10, pp. 865-874
Open Access | Times Cited: 172
Tom P. Freeman, Chandni Hindocha, Gianluca Baio, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 10, pp. 865-874
Open Access | Times Cited: 172
‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration
Tom P. Freeman, Valentina Lorenzetti
Addiction (2019) Vol. 115, Iss. 7, pp. 1207-1216
Open Access | Times Cited: 171
Tom P. Freeman, Valentina Lorenzetti
Addiction (2019) Vol. 115, Iss. 7, pp. 1207-1216
Open Access | Times Cited: 171
Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study
Alex Capano, Richard D. Weaver, Elisa Burkman
Postgraduate Medicine (2019) Vol. 132, Iss. 1, pp. 56-61
Open Access | Times Cited: 146
Alex Capano, Richard D. Weaver, Elisa Burkman
Postgraduate Medicine (2019) Vol. 132, Iss. 1, pp. 56-61
Open Access | Times Cited: 146
Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update
Benedikt Fischer, Tessa Robinson, Chris Bullen, et al.
International Journal of Drug Policy (2021) Vol. 99, pp. 103381-103381
Open Access | Times Cited: 132
Benedikt Fischer, Tessa Robinson, Chris Bullen, et al.
International Journal of Drug Policy (2021) Vol. 99, pp. 103381-103381
Open Access | Times Cited: 132
Association of cannabis potency with mental ill health and addiction: a systematic review
Kat Petrilli, Shelan Ofori, Lindsey A. Hines, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 9, pp. 736-750
Open Access | Times Cited: 126
Kat Petrilli, Shelan Ofori, Lindsey A. Hines, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 9, pp. 736-750
Open Access | Times Cited: 126
Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses
Will Lawn, Tom P. Freeman, Rebecca Pope, et al.
Psychopharmacology (2016) Vol. 233, Iss. 19-20, pp. 3537-3552
Open Access | Times Cited: 165
Will Lawn, Tom P. Freeman, Rebecca Pope, et al.
Psychopharmacology (2016) Vol. 233, Iss. 19-20, pp. 3537-3552
Open Access | Times Cited: 165
Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years
Mauro Maccarrone
Frontiers in Molecular Neuroscience (2017) Vol. 10
Open Access | Times Cited: 155
Mauro Maccarrone
Frontiers in Molecular Neuroscience (2017) Vol. 10
Open Access | Times Cited: 155
Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders
Alline C. Campos, Manoela V. Fogaça, Franciele Franco Scarante, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 154
Alline C. Campos, Manoela V. Fogaça, Franciele Franco Scarante, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 154
Can we make cannabis safer?
Amir Englund, Tom P. Freeman, Robin M. Murray, et al.
The Lancet Psychiatry (2017) Vol. 4, Iss. 8, pp. 643-648
Open Access | Times Cited: 140
Amir Englund, Tom P. Freeman, Robin M. Murray, et al.
The Lancet Psychiatry (2017) Vol. 4, Iss. 8, pp. 643-648
Open Access | Times Cited: 140
Emerging Evidence for Cannabis' Role in Opioid Use Disorder
Beth M. Wiese, Adrianne R. Wilson‐Poe
Cannabis and Cannabinoid Research (2018) Vol. 3, Iss. 1, pp. 179-189
Open Access | Times Cited: 136
Beth M. Wiese, Adrianne R. Wilson‐Poe
Cannabis and Cannabinoid Research (2018) Vol. 3, Iss. 1, pp. 179-189
Open Access | Times Cited: 136
Ketamine for the treatment of addiction: Evidence and potential mechanisms
Ivan Ezquerra-Romano, Will Lawn, Evgeny Krupitsky, et al.
Neuropharmacology (2018) Vol. 142, pp. 72-82
Open Access | Times Cited: 127
Ivan Ezquerra-Romano, Will Lawn, Evgeny Krupitsky, et al.
Neuropharmacology (2018) Vol. 142, pp. 72-82
Open Access | Times Cited: 127
High times for cannabis: Epigenetic imprint and its legacy on brain and behavior
Henrietta Szutorisz, Yasmin L. Hurd
Neuroscience & Biobehavioral Reviews (2017) Vol. 85, pp. 93-101
Open Access | Times Cited: 124
Henrietta Szutorisz, Yasmin L. Hurd
Neuroscience & Biobehavioral Reviews (2017) Vol. 85, pp. 93-101
Open Access | Times Cited: 124
Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
Celia J. A. Morgan, Tom P. Freeman, Chandni Hindocha, et al.
Translational Psychiatry (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 124
Celia J. A. Morgan, Tom P. Freeman, Chandni Hindocha, et al.
Translational Psychiatry (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 124
Increasing potency and price of cannabis in Europe, 2006–16
Tom P. Freeman, Teodora Groshkova, Andrew Cunningham, et al.
Addiction (2018) Vol. 114, Iss. 6, pp. 1015-1023
Open Access | Times Cited: 117
Tom P. Freeman, Teodora Groshkova, Andrew Cunningham, et al.
Addiction (2018) Vol. 114, Iss. 6, pp. 1015-1023
Open Access | Times Cited: 117
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues
Ethan B. Russo
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 116
Ethan B. Russo
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 116
